Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1726 to 1750 of 2524

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Antenatal and postnatal mental healthQS115
Nivolumab for treating advanced (unresectable or metastatic) melanomaTA384
Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits)HTG401
Major trauma: assessment and initial managementNG39
Major trauma: service deliveryNG40
Spinal injury: assessment and initial managementNG41
Fractures (non-complex): assessment and managementNG38
MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetesMIB51
Xpert Carba-R to identify people carrying carbapenemase-producing organismsMIB52
Healthcare-associated infectionsQS113
Irritable bowel syndrome in adultsQS114
Sunlight exposure: risks and benefitsNG34
Skin cancer preventionPH32
TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA383
Gastro-oesophageal reflux in children and young peopleQS112
Percutaneous coblation of the intervertebral disc for low back pain and sciaticaIPG543
Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciaticaIPG544
Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back painIPG545
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA377
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapyTA378
Nintedanib for treating idiopathic pulmonary fibrosisTA379
Panobinostat for treating multiple myeloma after at least 2 previous treatmentsTA380
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)TA382
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
EarlySense for heart and respiratory monitoring and predicting patient deteriorationMIB49

Results per page

  1. 10
  2. 25
  3. 50
  4. All